Lung cancer working group report
Asia needs a guideline for non-small-cell lung cancer because of differences in medical care, medical care insurance, ethnic variation and drug approval lag within Asian countries and compared with Western countries. Due to ethnic differences, drug dosages are often higher in the USA than in Japan....
Saved in:
Main Authors: | Saijo N., Fukuoka M., Thongprasert S., Ichinose Y., Mitsudomi T., Mok T., Ohe Y., Park K., Wu Y. |
---|---|
Format: | Journal |
Published: |
2017
|
Online Access: | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=77957280882&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/43250 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Chiang Mai University |
Similar Items
-
Lung cancer working group report
by: Nagahiro Saijo, et al.
Published: (2018) -
Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: Post hoc analyses from the IPASS study
by: Wu Y.-L., et al.
Published: (2014) -
Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non - small-cell lung cancer in Asia (IPASS)
by: Fukuoka M., et al.
Published: (2017) -
Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival
by: Lee C., et al.
Published: (2017) -
Lung cancer and quality of life
by: Thongprasert S.
Published: (2014)